American Journal of Clinical Oncology · 2010 · 126 citations · 35 references
Dose escalation up to 50 Gy in 5 fractions is feasible with SBRT for recurrent head and neck squamous cell carcinoma. Higher SBRT doses were associated with significantly higher LRC rates. Large tumor volume required higher SBRT doses to achieve optimal response rates compared with smaller tumor volume.
35
Bruce Brockstein, Daniel J. Haraf, Alfred Rademaker et al. · Annals of Oncology · 2004 · 368 citations · Full text